|
Notice to Readers: Updated Guidelines for the Use of Rifamycins for
the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
Guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis have been published previously
(1,2). New guidelines regarding interactions among these agents, with recommendations for their use from CDC and partners, are available at
http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm. Information
includes initial recommendations for the new PIs lopinavir/ritonavir,
atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs. The new recommendations
expand the use of rifampin with these antiretroviral drugs, which is critical in regions where rifabutin is unavailable. Periodic updates
will be posted to the website to provide clinicians with the latest information.
References
- CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20).
- CDC. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185--9.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication. |
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
Page converted: 1/22/2004
|
|
